These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17371484)

  • 1. Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatment.
    Müssig K; Knaus-Dittmann D; Schmidt H; Mörike K; Häring HU
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):604-5. PubMed ID: 17371484
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pain therapy. Extensive possibilities not adequately utilized].
    MMW Fortschr Med; 2005 May; 147(19):60-1. PubMed ID: 15940943
    [No Abstract]   [Full Text] [Related]  

  • 5. [Observational data in elderly pain patients show that fear of opioid therapy is unfounded].
    Junker U; Figge V
    MMW Fortschr Med; 2005 Jul; 147(27-28):43. PubMed ID: 16041941
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydromorphone-OROS formulation.
    Goforth HW
    Expert Opin Pharmacother; 2010 May; 11(7):1207-14. PubMed ID: 20402557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pain therapy with semisynthetic opioids. Patients have opioid-type side effects more rarely].
    Sohn W
    MMW Fortschr Med; 2003 Jul; 145(27-28):50. PubMed ID: 14587190
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pain therapy in patients with tumors. According to graduated schedule and hourly plan].
    MMW Fortschr Med; 2003 Oct; 145(40):53. PubMed ID: 14603608
    [No Abstract]   [Full Text] [Related]  

  • 9. Secondary adrenal insufficiency due to opiate therapy - another differential diagnosis worth consideration.
    Schimke KE; Greminger P; Brändle M
    Exp Clin Endocrinol Diabetes; 2009 Nov; 117(10):649-51. PubMed ID: 19373753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
    O'Connor AB; Zwemer FL; Hays DP; Feng C
    Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iatrogenic occipital osteomyelitis.
    Medvedev G; Palacios E; Jones W
    Ear Nose Throat J; 2009 Jan; 88(1):720-1. PubMed ID: 19172563
    [No Abstract]   [Full Text] [Related]  

  • 12. Opioid safety: is your patient at risk for respiratory depression?
    Smith LH
    Clin J Oncol Nurs; 2007 Apr; 11(2):293-6. PubMed ID: 17573279
    [No Abstract]   [Full Text] [Related]  

  • 13. Opioid withdrawal syndrome on switching from hydromorphone to alfentanil.
    McMunnigall F; Welsh J
    Palliat Med; 2008 Mar; 22(2):191-2. PubMed ID: 18372384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pain treatment during pregnancy and opiate addiction in both mother and child].
    Lakartidningen; 1988 Feb; 85(5):346-7. PubMed ID: 2451097
    [No Abstract]   [Full Text] [Related]  

  • 15. [The role of hydromorphone in pain killing].
    Telekes A
    Lege Artis Med; 2008 Oct; 18(10):675-9. PubMed ID: 19227610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Delayed action and rapidly effective in combination. Hydromorphone--already a WHO stage 3 drug].
    MMW Fortschr Med; 2006 May; 148(19):47. PubMed ID: 16736708
    [No Abstract]   [Full Text] [Related]  

  • 18. The side effects of morphine and hydromorphone patient-controlled analgesia.
    Hong D; Flood P; Diaz G
    Anesth Analg; 2008 Oct; 107(4):1384-9. PubMed ID: 18806056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride.
    Katcher J; Walsh D
    J Pain Symptom Manage; 1999 Jan; 17(1):70-2. PubMed ID: 9919868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.